Oral Calcitriol With Ketoconazole in CRPC

• Status: Terminated
• Trial end date: 2018-02-28

Summary

The aim of this study is to estimate the PSA response rate with the use of ketoconazole (400mg QD + hydrocortisone 20mg AM, 10 mg PM) among men with CRPC in whom disease has progressed despite abiraterone

• Phase: Phase 2

Details

• Lead Sponsor: Donald Trump, MD
• Treatments: Calcitriol; Cortisol succinate; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Ketoconazole; Vitamin D